Supraflex Cruz evidence presented at TCT 2025
In November 2025, EUKON shared an update from Sahajanand Medical…
FAVOR III China: QFR-Guided PCI Strategy vs. Angiography-Guided Strategy
FAVOR III China has bees published on Lancet and simultaneously presented at TCT 2021
It’s the first randomized trial to compare the clinical outcomes of PCI guided by angiography-derived physiological lesion selection and standard angiography-guided lesion selection. QFR guidance resulted in a 35% risk reduction in the 1-year rate of major adverse cardiac events, a composite of death from any cause, myocardial infarction, or ischaemia driven revascularization, compared with standard angiography guidance. READ MORE
Latest News:
LaaGuarder: first European clinical use announced by EUKON
In January 2026, EUKON announced the first clinical use in…
Supraflex Cruz NEVO now available to Italian cath labs
EUKON announced the availability of Supraflex Cruz NEVO to Italian…